Clinical Trial

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-09-22; most recent amendment 2026-05-30.
Status change: Not Yet Recruiting → Recruiting 2025-12-02
Trial Details
NCT Number NCT07197554
Lead Sponsor SEED Therapeutics, Inc.
Conditions Advanced Solid Tumors, Ewing Sarcoma, Hepatocellular Carcinoma (HCC), Biliary Tract Cancer (BTC)
Enrollment 171 participants
Start Date 2025-12-01
Primary Completion 2029-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-02